Table 1 Demographic and clinical characteristics of the study cohort
Characteristic at baseline | Nucleoside analog regimen (n = 73) | Nucleotide analog regimen (n = 29) | P value |
|---|---|---|---|
Age (years) | 52.1 ± 11.3 | 56.6 ± 6.2 | 0.011* |
Male sex (%) | 49 (67.1 %) | 24 (82.7 %) | 0.114 |
Weight (kg) | 67.8 ± 14.4 | 66.5 ± 14.4 | 0.645 |
Diabetes mellitus (%) | 9 (12.3 %) | 4 (13.8 %) | 0.841 |
Hypertension (%) | 13 (17.8 %) | 11 (37.9 %) | 0.031* |
Cirrhosis (%) | 4 (5.5 %) | 3 (10.3 %) | 0.381 |
Duration of treatment (months) | 44.5 (3–105) | 52.0 (3–103) | 0.643 |
HBV e antigen positive (%) | 21 (28.8 %) | 11 (37.9 %) | 0.364 |
Serum ALT concentration (U/l) | 56 (15–479) | 33 (13–340) | 0.125 |
HBV DNA concentration (log IU/ml) | 4.99 ± 1.73 | 4.86 ± 1.40 | 0.735 |
Serum creatinine concentration (mg/dl) | 0.87 ± 0.18 | 0.84 ± 0.17 | 0.417 |